BREAKING: Futures Fall With Market At Highs; Tesla Climbs After two high-profile failures, Pfizer (PFE) is clawing deeper into the obesity space with the $4.9 billion acquisition of Metsera (MTSR). Metsera, a small clinical-stage biotech company, is working on multiple approaches to weight loss. It has a potential weekly and monthly GLP-1-targeting drug — similar to Novo Nordisk's Wegovy — and a drug dosed monthly that mimics amylin. Amylin plays a role in regulating blood sugar levels, appetite and gastric ...

Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combination therapy candidates.“Obesity is a large and growing space with over 200 health conditions associated with it,” said Pfizer CEO Albert Bourla. . The acquisition “propels” Pfizer into a “key therapeutic area,” he added.Also Read: Pfizer, Moderna, BioN ...

Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market. Pfizer said it will pay an initial $47.50 a share in cash for Metsera, a nearly 43% premium to the biotech company's Friday's closing price of $33.32. That gives the deal an enterprise value of $4.9 billion. The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulat ...

Thomas Fuller / SOPA Images / LightRocket via Getty Images Metsera shares skyrocketed after Pfizer agreed to purchase the biopharma firm Key Takeaways Pfizer said it would pay as much as $7.3 billion for Metsera as it looks to profit from soaring demand for weight-loss medicines. Metsera investors will get $47.50 per share for each share they own, plus up to an additional $22.50 per share if the biopharma's combination treatment for obesity meets certain thresholds. The news sent Metsera shares soari ...

公司股东激励 - 股东可能获得重大分红 前提是达到特定里程碑 [1]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Metsera, Inc. (NASDAQ: MTSR) to Pfizer Inc. is fair to Metsera shareholders. Under the terms of the proposed transaction, Metsera shareholders will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. Halp. ...

1. 9月22日(周一)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.30%，标普500指数期货跌0.26%，纳指期货跌0.32%。 | ■ US 30 | 46,175.90 | 46,318.30 | 46,127.00 | -138.70 | -0.30% | | --- | --- | --- | --- | --- | --- | | ■ US 500 | 6,647.30 | 6,666.20 | 6,640.50 | -17.10 | -0.26% | | ■ US Tech 100 | 24,548.00 | 24,644.00 | 24,517.50 | -78.30 | -0.32% | 2. 截至发稿，德国DAX指数跌0.75%，英国富时100指数涨0.01%，法国CAC40指数跌0.32%，欧洲斯托克50指数跌0.41%。 | I 德國DAX30 | 23,466.85 | 23,588.35 | 23,421.99 | -178.40 | -0.75% | | --- | --- | --- | --- | --- | --- | | 淵 英國富時100 | 9,217.9 ...

智通财经APP获悉，辉瑞(PFE.US)同意以约49亿美元的企业价值收购肥胖症药物研发初创公司 Metsera(MTSR.US)，此举旨在强化其研发管线。此前，该公司一款关键减肥药研发受挫。 这家美国制药商在周一的声明中表示，将以每股47.50美元的现金收购Metsera，若达成三项特定监管里 程碑，还将额外支付每股最高22.50美元。该交易较Metsera上周五收盘价溢价43%。截至发稿，Metsera 盘前涨59.72%，报53.22美元。 新冠疫情过后，辉瑞正致力于业务重整，将希望寄托于尚未经过验证的新药研发管线，以接替其老化产 品。作为新一代肥胖症药物研发中有望脱颖而出的企业之一，Metsera正在开发多款实验性减肥药物， 其中包括一款注射剂，其给药频率可能低于市场主流产品Wegovy和Zepbound。 该公司研发的药物MET-233i在最近一项研究中，帮助患者在36天内减重高达8.4%。该药物仍处于早期 开发阶段，这意味着距离上市还有数年时间。 彭博行业研究的迈克尔·沙阿表示，MET-233i"可能成为肥胖症治疗领域最具潜力的同类最佳药物"。 ...

At 7:25 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs. ...